Quotient Sciences
Buying intent
31 tracked signals | Top 15 topics are below | Product and Sales are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Quotient Sciences's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
4d ago
8d ago
9d ago
16d ago
9d ago
4d ago
28d ago
4d ago
23d ago
13d ago
4d ago
4d ago
4d ago
9d ago
17d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Quotient Sciences
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileQuotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions,
Top accounts researching Quotient Sciences
names withheld on the public pageThese are companies whose own people brought up Quotient Sciences unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
129,094 companies · 649,540 people are researching Artificial Intelligence
Quotient Sciences's own team shows 7 signals on this topic. No one outside Quotient Sciences has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Drug Development1,165 cos · 3,772 people
- Clinical Trials3,463 cos · 13,523 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Leadership — 2 people; Sales — 2 people; Product — 1 person; HR / Talent — 1 person
What's been said
public posts by Quotient Sciences's teamNo public post naming Quotient Sciences has surfaced in the past year, so this is what Quotient Sciences's own team is posting about publicly — their topics, in their words.
Attending #CPHIAmericas ? Let's connect to discuss your program needs and explore how #QuotientSciences can support you through our #TranslationalPharmaceutics ® platform. This disruptive approach to drug development seamlessly integrates formulation development, #drugproduct manufacturing, and #clinical testing. Schedule a time to meet at the event today: https://bit.ly/4u9JhMk
May 2026Excipient selection is one of the most critical (and time-consuming) steps in early-phase pharma and I know that getting excipients right early prevents significant scale-up issues downstream. Building on last week’s post, here is 𝗖𝗵𝗮𝗽𝘁𝗲𝗿 𝟭𝗕 𝗼𝗳 𝗣𝗿𝗲𝗙𝗼𝗿𝗺𝗔𝗶: 𝗘𝘅𝗰𝗶𝗽𝗶𝗲𝗻𝘁 𝗖𝗼𝗺𝗽𝗮𝘁𝗶𝗯𝗶𝗹𝗶𝘁𝘆. (24-second walkthrough below) The tool below scans known risk factors against your API and generates a predictive compatibility matrix before you run a single experiment. Goal: Select the right excipient on the first try and reduce the number of trials. what other features would make this companion more useful? (Link to Chapter 1A in the first comment) Hope this inspires better workflows. ⚠️ Personal project. Synthetic data only. #Preformulation #ExcipientCompatibility #PharmaSci #OperationalExcellence #AIinPharma #FormulationDevelopment
Apr 2026